FXYD3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival

Nathalie B. Rasko; Christopher B. Nahm; John Turchini; Rachel Teh; Helge Rasmussen; Sooin Byeon; Sumit Sahni; Jaswinder S. Samra; Anthony J. Gill; Anubhav Mittal

doi:10.1002/cam4.70500

FXYD3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival

Nathalie B. Rasko, Christopher B. Nahm, John Turchini, Rachel Teh, Helge Rasmussen, Sooin Byeon, Sumit Sahni, Jaswinder S. Samra, Anthony J. Gill, Anubhav Mittal^*

^*Corresponding author for this work

Macquarie Medical School

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993–2014). Method: FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results: 145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion: Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.

Original language	English
Article number	e70500
Pages (from-to)	1-6
Number of pages	6
Journal	Cancer Medicine
Volume	14
Issue number	1
DOIs	https://doi.org/10.1002/cam4.70500
Publication status	Published - 9 Jan 2025

Bibliographical note

Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

FXYD3
MAT-8
pancreatic cancer
pancreatic ductal adenocarcinoma
prognosis
survival

Access to Document

10.1002/cam4.70500Licence: CC BY

Publisher version (open access)Final published version, 327 KBLicence: CC BY

Cite this

@article{c723fba4afe047f9950c7ffc7941221e,

title = "FXYD3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival",

abstract = "Background: FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993–2014). Method: FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results: 145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5\%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95\% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion: Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.",

keywords = "FXYD3, MAT-8, pancreatic cancer, pancreatic ductal adenocarcinoma, prognosis, survival",

author = "Rasko, \{Nathalie B.\} and Nahm, \{Christopher B.\} and John Turchini and Rachel Teh and Helge Rasmussen and Sooin Byeon and Sumit Sahni and Samra, \{Jaswinder S.\} and Gill, \{Anthony J.\} and Anubhav Mittal",

note = "Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2025",

month = jan,

day = "9",

doi = "10.1002/cam4.70500",

language = "English",

volume = "14",

pages = "1--6",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley \& Sons",

number = "1",

}

TY - JOUR

T1 - FXYD3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival

AU - Rasko, Nathalie B.

AU - Nahm, Christopher B.

AU - Turchini, John

AU - Teh, Rachel

AU - Rasmussen, Helge

AU - Byeon, Sooin

AU - Sahni, Sumit

AU - Samra, Jaswinder S.

AU - Gill, Anthony J.

AU - Mittal, Anubhav

N1 - Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2025/1/9

Y1 - 2025/1/9

N2 - Background: FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993–2014). Method: FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results: 145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion: Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.

AB - Background: FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993–2014). Method: FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results: 145 of 180 PDAC tumour specimens were FXYD3-immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log-rank p = 0.9718). FXYD3 expression correlated positively with late-stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion: Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.

KW - FXYD3

KW - MAT-8

KW - pancreatic cancer

KW - pancreatic ductal adenocarcinoma

KW - prognosis

KW - survival

UR - https://www.scopus.com/pages/publications/85214687098

U2 - 10.1002/cam4.70500

DO - 10.1002/cam4.70500

M3 - Article

C2 - 39783776

AN - SCOPUS:85214687098

SN - 2045-7634

VL - 14

SP - 1

EP - 6

JO - Cancer Medicine

JF - Cancer Medicine

IS - 1

M1 - e70500

ER -

FXYD3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this